AzTrials
AzTrials

Metabolic-associated Fatty Liver DiseaseEarly Phase 1NCT07185932

Efficacy and Safety of Rifaximin in Treating MAFLD

A Early Phase 1 study testing Rifaximin (Xifaxan) in people with Metabolic-associated Fatty Liver Disease, run by Shanghai Changzheng Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression. Target Population: patients diagnosed with MAFLD. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Metabolic-associated Fatty Liver Disease
What is being tested?
Rifaximin (Xifaxan)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteChina
Study dates
10 Aug 2024to 31 Dec 2027
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing and able to provide written informed consent;
  • Aged 18 to 75 years, regardless of gender;
  • Diagnosed with fatty liver disease within the past 6 months;
  • Presence of at least one of the following metabolic abnormalities:
  • Overweight or obesity (BMI ≥23 kg/m²) (2) Type 2 diabetes (T2DM) (3) Clinical evidence of metabolic dysfunction (defined as meeting at least two of the following criteria): A. Waist circumference ≥90 cm for males or ≥80 cm for females B. Blood pressure ≥130/85 mmHg and/or diagnosed hypertension under treatment C. Fasting plasma triglycerides ≥1.7 mmol/L (150 mg/dL) or diagnosed hypertriglyceridemia under treatment D. Fasting HDL-C <1.0 mmol/L (40 mg/dL) for males or <1.3 mmol/L (50 mg/dL) for females, or diagnosed dyslipidemia under treatment E. Prediabetes: fasting glucose 5.6-6.9 mmol/L (100-125 mg/dL) or 2-hour postprandial glucose 7.8-11.0 mmol/L (140-199 mg/dL) or HbA1c 5.7%-6.4% (39-47 mmol/mol) F. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score ≥2.5 G. Plasma high-sensitivity C-reactive protein (hs-CRP) >2 mg/L 5. Liver fat content ≥8% as measured by MRI proton density fat fraction (MRI-PDFF).

Who cannot join

  • Cirrhosis - Confirmed by clinical, laboratory, imaging, and/or liver biopsy.
  • Chronic liver disease of other etiologies (e.g., viral/autoimmune hepatitis, alcoholic liver disease, drug-induced liver injury)
  • Secondary hepatic steatosis (e.g., drug-induced, total parenteral nutrition-related, or hypothyroidism-associated);
  • Recent use of intestinal flora-modifying agents, or unstable regimens of medications (including hepatoprotectants, metformin, thiazolidinediones, fibrates, statins, et al) within 4 weeks prior to enrollment;
  • Agents with potential effects on MAFLD progression administered within 12 weeks prior to enrollment, excluding those maintained at stable doses for ≥24 weeks (e.g., Glucagon-like peptide-1 receptor agonists, Dipeptidyl peptidase IV inhibitors, Obeticholic acid, Sodium-glucose cotransporter 2 inhibitors, Resmetirom or anti-obesity medications)
  • Poorly controlled diabetes (HbA1c >9%)
Show all 16Show fewer
  • Jaundice (total bilirubin ≥85 μmol/L), or Renal dysfunction (serum creatinine ≥1.2 × ULN)
  • History of bariatric surgery
  • Active or suspected malignancy
  • Severe systemic conditions - Including: Inflammatory diseases (e.g., connective tissue disorders), Biliary/pancreatic disorders, Chronic/acute infections, Severe cardiovascular, pulmonary, or hematologic diseases, Myocardial infarction or stroke within 6 months, Psychiatric disorders
  • HIV infection
  • Known hypersensitivity to rifaximin
  • MRI contraindications - Including: Metal implants, Claustrophobia, Body size exceeding scanner capacity
  • Pregnancy, lactation, or planned pregnancy
  • Participation in another drug trial within 3 months
  • Other conditions deemed unsuitable by investigators

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

CHUAN YIN, M.D. contact

+8613482705212

ilse1225@163.com

China1 site, 1 recruiting
  • Changzheng Hospital, Naval Medical University, shanghai, China

    Shanghai, Shanghai Municipality, 200003

    13482705212, ilse1225@163.com

    Recruiting

Other trials in China

About this study

Official title: Efficacy and Safety of Rifaximin in Treating Metabolic Associated Fatty Liver Disease: A Pilot Trial

Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.

Target Population: patients diagnosed with MAFLD. Intervention: this single-center, single-arm exploratory study will enroll up to 40 eligible MAFLD patients who meet the inclusion criteria, do not meet any exclusion criteria, and provide written informed consent. Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks. Patients will be advised to maintain their usual physical activity and adhere to a recommended dietary plan (e.g., Mediterranean diet). Concurrent therapies such as hepatoprotective agents, lipid-lowering medications, and antihypertensive treatments will remain unchanged, with close monitoring of relevant parameters. No additional prescription or over-the-counter drugs that may affect fatty liver progression or alter gut microbiota composition will be permitted during the study.

Read more

The primary endpoint will be assessed at 24 weeks. If liver proton density fat fraction (PDFF) remains ≥ 8% after 24 weeks of rifaximin therapy, treatment will be extended for an additional 12 weeks, followed by reevaluation of PDFF changes. The maximum total treatment duration will not exceed 48 weeks. All patients will undergo a 24-week post-treatment follow-up period after discontinuation of rifaximin.

Investigational Drug: Rifaximin (Alfa Wassermann S.p.A., Italy).

Being tested
Rifaximin (Xifaxan)
Keywords
metabolic-associated fatty liver disease, Rifaximin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rifaximin (Xifaxan)Drug

    Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.

Study groups in NCT07185932
Study groupRoleWhat they receive
Rifaximin treatment groupExperimentalParticipants will receive oral rifaximin.
Receives: Drug: Rifaximin (Xifaxan)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The change in liver fat content measured by MRI at 24 weeks of treatment.

    Absolute and relative changes in MRI-measured liver proton density fat fraction (PDFF) at 24 weeks compared to baseline.

    Measured: From enrollment to the end of treatment at 24 weeks

Secondary outcomes (22)
  1. Proportion of patients achieving ≥30% reduction in liver fat content measured by MRI-PDFF at 24 weeks of treatment compared to baseline

    Proportion of patients achieving ≥30% reduction in liver fat content measured by MRI-PDFF at 24 weeks of treatment compared to baseline

    Measured: From enrollment to the end of treatment at 24 weeks

  2. The change in liver fat content measured by MRI-PDFF at 12 weeks of treatment.

    Absolute and relative changes in MRI-measured liver PDFF at 12 weeks compared to baseline.

    Measured: From enrollment to the end of treatment at 24 weeks

  3. Proportion of patients achieving ≥30% reduction in liver fat content (PDFF) measured by MRI at 12 weeks of treatment compared to baseline.

    The proportion of patients whose liver fat content (PDFF), assessed via MRI, decreased by ≥30% from baseline after 12 weeks of treatment.

    Measured: From enrollment to the end of treatment at 24 weeks

  4. Changes in liver function indicators after 12 weeks of treatment compared to baseline.

    Changes in liver function parameters from baseline after 12 weeks of treatment.

    Measured: From enrollment to the end of treatment at 12 weeks

  5. Changes in liver function indicators after 24 weeks of treatment compared to baseline.

    Changes in liver function indicators after 24 weeks of treatment compared to baseline.

    Measured: From enrollment to the end of treatment at 24 weeks

  6. Change in liver fat content assessed via FibroScan after 12 weeks of treatment compared to baseline.

    Change in controlled attenuation parameter (CAP) values, measured by FibroScan, from baseline after 12 weeks of therapy

    Measured: From enrollment to the end of treatment at 12 weeks

  7. Change in liver fat content assessed via FibroScan after 24 weeks of treatment compared to baseline.

    Change in controlled attenuation parameter (CAP) values, measured by FibroScan, from baseline after 24 weeks of therapy

    Measured: From enrollment to the end of treatment at 24 weeks

  8. Changes in fatty liver index (FLI) after 12 and 24 weeks of treatment compared to baseline.

    FLI is utilized to assess the severity of hepatic steatosis. Its calculation formula is based on laboratory and anthropometric measurements, including triglyceride (TG) and gamma-glutamyl transferase (GGT) levels, body mass index (BMI), and waist circumference (WC).

    FLI = (e^(0.953 * ln(triglycerides) + 0.139 * BMI + 0.718 * ln(ggt) + 0.053 * waist circumference - 15.745)) / (1 + e^(0.953 * ln(triglycerides) + 0.139 * BMI + 0.718 * ln(ggt) + 0.053 * waist circumference - 15.745)) * 100

    A FLI value below 30 can be used to rule out steatosis (sensitivity = 87%; negative likelihood ratio [LR-] = 0.2), while a FLI value equal to or above 60 can be used to rule in hepatic steatosis.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  9. Changes in NAFLD-liver fatty score(NAFLD-LFS)after 12 and 24 weeks of treatment compared to baseline.

    NAFLD-LFS Calculation Formula: NAFLD-LFS = -2.89 + 0.45 × Type 2 Diabetes (yes=2, no=0) + 1.18 × Metabolic Syndrome (yes=1, no=0) + 0.15 × Insulin (mU/L) + 0.04 × AST (U/L) - 0.94 × (AST/ALT Ratio).

    Interpretation of Scores:

    NAFLD-LFS < -1.0: Suggests low liver fat content and a low likelihood of significant steatosis. -1.0 ≤ NAFLD-LFS ≤ 0.5: Intermediate range; further evaluation with additional tests (e.g., imaging or biopsy) is recommended. NAFLD-LFS > 0.5: Indicates high liver fat content and the presence of significant steatosis, requiring clinical intervention.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  10. Changes in AST-to-Platelet Ratio Index (APRI) after 12 and 24 weeks of treatment compared to baseline.

    APRI is calculated using the following formula:

    APRI = [ (AST Level (U/L) / AST ULN (Upper Limit of Normal)) / Platelet Count (10⁹/L) ] × 100

    Interpretation:

    APRI < 0.5: Suggests the absence of significant fibrosis (high negative predictive value).

    APRI > 2.0: Highly indicative of cirrhosis (high positive predictive value). Intermediate values (0.5 ≤ APRI ≤ 2.0): Further evaluation with additional tests-such as liver elastography, FIB-4 index, or liver biopsy-is recommended for accurate assessment.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  11. Changes in Fibrosis 4 (FIB-4) Score after 12 and 24 weeks of treatment

    The FIB-4 index is primarily used to stratify the risk of liver fibrosis and is calculated using the following formula: FIB-4= Age (years) × AST (U/L)/ [Platelet Count (10⁹/L)×√ALT(U/L)]. The criteria are categorized as follows: Low Risk (FIB-4 < 1.3) suggests minimal or no fibrosis (F0-F1). Liver biopsy or elastography may be deferred in such cases. Intermediate Risk (1.3 ≤ FIB-4 ≤ 2.67): Further evaluation with additional tests-such as liver elastography, APRI, or liver biopsy-is recommended. Significant fibrosis (F2-F3) may be present, warranting closer monitoring. High Risk (FIB-4 > 2.67): Highly suggestive of advanced fibrosis or cirrhosis (F3-F4). Confirmatory tests like elastography or liver biopsy should be prioritized. This range has a high positive predictive value.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  12. Changes in NAFLD fibrosis score (NFS) after 12 and 24 weeks of treatment compared to baseline.

    NFS calculation formula: NFS= [-1.675+0.037×Age (years)+0.094×BMI(kg/m2+1.13×IFG/Diabetes (yes = 1, no = 0) +0.99)× (AST/ALT Ratio) +0.013×PLT(×109/L)-0.66×ALB(g/dl)]

    Interpretation Guidelines:

    NFS < -1.455: Low probability of significant fibrosis (F2-F4). NFS > 0.676: High probability of advanced fibrosis (F3-F4). NFS between -1.455 and 0.676: Indeterminate range; further evaluation with additional tests (e.g., elastography or liver biopsy) is recommended.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  13. Changes in FibroScan-AST (FAST) Score after 12 and 24 weeks of treatment compared to baseline.

    The FAST Score is a non-invasive composite index used to assess the likelihood of both significant fibrosis (≥F2) and active steatohepatitis (NASH) in patients withMASLD. It integrates Liver Stiffness Measurement (LSM) obtained via FibroScan® and the serum biomarker AST.

    FAST Score Calculation Formula: FAST = e^(-1.65 + 1.07 × ln(LSM) + 2.66 × 10^(-8) × AST^3 - 63.3 × AST^(-1) - 0.009 × PLT) / (1 + e^(-1.65 + 1.07 × ln(LSM) + 2.66 × 10^(-8) × AST^3 - 63.3 × AST^(-1) - 0.009 × PLT)).

    Interpretation Guidelines:

    FAST < 0.35: Low probability of significant fibrosis (≥F2) with active inflammation (NASH). Negative predictive value >90%. Liver biopsy may be avoided.

    FAST > 0.67: High probability of both significant fibrosis (≥F2) and active inflammation (NASH). Positive predictive value >70%. Further evaluation or intervention is recommended.

    FAST between 0.35-0.67: Gray zone; comprehensive assessment with additional methods.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  14. Changes in Body Mass Index (BMI) at 12 and 24 weeks of treatment compared to baseline.

    BMI calculation Formula:

    BMI = Weight (kilograms) ÷ [Height (meters)]²

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  15. Changes in Waist circumference (WC) at 12 and 24 weeks of treatment compared to baseline.

    Waist circumference (WC) is measured 3 cm above the navel.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  16. Changes in visceral adipose tissue (VAT) at 12 and 24 weeks of treatment compared to baseline.

    VAT was quantified using 3D Slicer software by manually segmenting regions of interest (ROIs) within the intra-abdominal cavity on MRI images at the level of the third lumbar vertebra (L3).

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  17. Changes in abdominal subcutaneous adipose tissue (ASAT) from baseline after 12 and 24 weeks of therapy.

    ASAT volume was quantified using 3D Slicer software by manually segmenting regions of interest (ROIs) within the subcutaneous fat compartment on MRI images at the level of the third lumbar vertebra (L3).

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  18. Changes in Cholesterol from baseline after 12 and 24 weeks of therapy.

    Cholesterol testing should be performed in the morning after an overnight fast.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  19. Changes in triglyceride from baseline after 12 and 24 weeks of therapy.

    Triglyceride testing should be performed in the morning after an overnight fast.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  20. Changes in Hemoglobin A1c (HbA1c) from baseline after 12 and 24 weeks of therapy.

    Change from baseline in HbA1c absolute concentration (mmol/mol) and percentage of total hemoglobin (%) after 12 and 24 weeks of therapy.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  21. Changes in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from baseline after 12 and 24 weeks of therapy.

    HOMA-IR Calculation Formula: HOMA-IR = [Fasting Insulin (μIU/mL) × Fasting Glucose (mmol/L)] / 22.5. Increase in HOMA-IR suggests worsening insulin resistance. Decrease in HOMA-IR indicates improved insulin sensitivity.

    Measured: From enrollment to the end of treatment at 12 and 24 weeks

  22. The frequency and severity of treatment-related adverse events (AEs) as assessed by CTCAE 5.0.

    The safety assessment involved monitoring changes in symptoms, vital signs, and laboratory parameters during treatment.

    Measured: From enrollment to the end of treatment at 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Sep 2025
  2. Study start10 Aug 2024
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07185932
Sponsor's protocol ID
CZXH2021001.02
Status last verified
Sep 2025
First submitted
21 Aug 2025
Last updated
22 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Rifaximin (Xifaxan) in people with Metabolic-associated Fatty Liver Disease, run by Shanghai Changzheng Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact CHUAN YIN, M.D. (+8613482705212, ilse1225@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The change in liver fat content measured by MRI at 24 weeks of treatment. (time frame: From enrollment to the end of treatment at 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in